Live
- Regional parties will continue to be future of Indian politics, says BRS
- Most Americans not aware that alcohol ups cancer risk: Survey
- Bengal bypolls: Trinamool Congress sweeps up all six Assembly constituencies, Mamata thanks voters (4th Lead)
- BJP wins five Rajasthan bypolls seats, Congress one
- VHP's 'Sant Samavesh' discusses Waqf issue, religious conversions, autonomy for temples
- Famous Chinar boat race organised in J&K's Dal Lake
- Entire Maharashtra behind PM Modi: Devendra Fadnavis
- Tragic Road Accident in Anantapur District Claims Four Lives
- I bow down to voters' decision: Kumaraswamy’s son on bypolls defeat
- Priyanka's resemblance with Indira Gandhi only in appearance: Robert Vadra
Covaxin could be back-up for now, says AIIMS chief
Covaxin could be back-up for now, says AIIMS chief
Bharat Biotech's coronavirus vaccine, which is still undergoing clinical trial, is likely to be the ‘back-up’ vaccine in the coming days, Dr Randeep Guleria, the chief of Delhi's All-India Institute of Medical Sciences, said on Sunday as two vaccines got emergency approval from the country's drug regulator
New Delhi: Bharat Biotech's coronavirus vaccine, which is still undergoing clinical trial, is likely to be the 'back-up' vaccine in the coming days, Dr Randeep Guleria, the chief of Delhi's All-India Institute of Medical Sciences, said on Sunday as two vaccines got emergency approval from the country's drug regulator.
Politics has started over the approval to Covaxin, with several Opposition parties pointing out that the vaccine was approved without the full process.
Congress's Shashi Tharoor tweeted, "The Covaxin has not yet had Phase 3 trials. Approval was premature and could be dangerous. @drharshvardhan should please clarify. Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime".
"I feel that in the coming days it is the Serum Institute vaccine that will be the main vaccine, Bharat Biotech only a backup for emergency use in case of reinfection," Dr Randeep Guleria said.
"By that time, they will get their dosage ready and by the time they will get the data which will be able to show that the phase 3 data is robust and they have enough events to show that it is efficacious and it is safe, we will be able to have that vaccine available. But the first few weeks, it will be the serum institute vaccine which will be rolled out. It has 50 million doses available," Dr Guleria said.
Covaxin, the clinical trial of which is being conducted in collaboration with the Indian Council of Medical Research, has completed only its I and II phase trials.
